Home » Stocks » AMAM

Ambrx Biopharma, Inc. (AMAM)

Stock Price: $15.95 USD -0.28 (-1.73%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $16.00 +0.05 (0.31%) Jun 22, 7:51 PM
Market Cap 600.83M
Revenue (ttm) 13.67M
Net Income (ttm) -16.54M
Shares Out 37.67M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $15.95
Previous Close $16.23
Change ($) -0.28
Change (%) -1.73%
Day's Open 16.20
Day's Range 15.56 - 16.33
Day's Volume 69,660
52-Week Range 14.94 - 18.00

News

Hide News

Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics (EPBs), today announced the pricing of its ini...

5 days ago - Business Wire

Ambrx Biopharma, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

3 weeks ago - SEC

About AMAM

Ambrx Biopharma is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using our proprietary expanded genetic code technology platform that allows us to incorporate, in a site-specific manner, synthetic amino acids (SAAs) into proteins within living cells. Our precision engineering capabilities and the broad applicability of our expanded genetic code technology platform have the potential to enhance and enable the therapeutic functions of conventional biologics and bio-... [Read more...]

Industry
Biological Products
IPO Date
Jun 18, 2021
CEO
Feng Tian, Ph.D.
Employees
70
Stock Exchange
NYSE
Ticker Symbol
AMAM
Full Company Profile

Financial Performance

In 2020, AMAM's revenue was $13.67 million, an increase of 32.59% compared to the previous year's $10.31 million. Losses were -$17.84 million, -20.05% less than in 2019.

Financial Statements